| Pharmaceuticals | Manufacturing and marketing general medicines across anti-infectives, dermatology, cardiology, respiratory, and nutritionals. | Strong brand equity, extensive sales network, R&D capabilities, and parent company GSK support. | B2B and B2C focus; includes hospitals, clinics, doctors, and retail pharmacies across India. | Specialty medicines, branded generics and patented drugs show highest margins. | 3200 | 85 | Revenue through prescription drug sales to hospitals, pharmacies, and healthcare providers mainly in India. | Direct sales with standard industry pricing, driven by prescriptions and brand reputation. | New product launches, specialty medicine expansions, competitive brand positioning and market share gains. | Augmentin, Calpol, Eltroxin, Tenovate, Neosporin, T-Bact |
| Vaccines | Production and distribution of pediatric and adult vaccines for infectious diseases and immunization programs. | Strong manufacturing capability, leading vaccine portfolio in India, and global technological platforms from GSK. | B2B focus with government health departments, hospitals, clinics and international organizations. | Innovative adult vaccines such as Shingrix with premium pricing and strong demand. | 550 | 15 | Sales of vaccines to government immunization programs, hospitals, and private healthcare providers. | Contract sales with tenders and institutional customers; volume-based pricing strategies. | Vaccine portfolio expansion, adult immunization awareness, and partnership with healthcare providers. | Shingrix, Priorix-Tetra, Fluarix Tetra, Infanrix Hexa, Varilrix, Havrix |
